Metaplastic carcinomas of the breast

Chao, Tzu‐Chieh; Wang, Chia‐Siu; Chen, Shin‐Cheh; Chen, Miin-Fu

doi:10.1002/(sici)1096-9098(199908)71:4<220::aid-jso3>3.0.co;2-l

Cited by 103 publications

(94 citation statements)

References 14 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The absence of hormone receptor expression on tumors restricts the application of hormonal therapy. Chao et al (12) reported no survival advantage of post-operative radiotherapy and various neoadjuvant chemotherapy regimens; however, different and/or mixed chemotherapy regimens and dose schedules may be more effective. Therefore, traditional surgery is the preferred treatment choice (2).…”

Section: Pathological Type Of Carcinoma Sonography ------------------mentioning

confidence: 99%

Metaplastic carcinoma of the breast: Imaging and pathological features

Bian

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Metaplastic carcinoma of the breast is a rare form of breast cancer. The aim of the present study was to investigate the imaging and pathological features of metaplastic carcinoma. The features identified on mammography and sonography were retrospectively reviewed in 13 women with metaplastic carcinoma of the breast. The results from the mammographs and sonographs were additionally evaluated using immunohistochemical staining for the expression of the estrogen receptor (ER) and progesterone receptor (PR), receptor tyrosine-protein kinase erbB-2 (CerbB-2) and P53. The most common features observed in the mammographs were as follows: Irregular and oval shaped masses, 53.8 and 46.2%, respectively; spiculated and circumscribed margins, each 30.8%; and high and marginally high density masses, 69.2 and 30.8%, respectively. The most common sonography features observed were as follows: Hypoechoic masses, 84.6%; complex echogenicity, 76.9%; irregular, round and oval shaped masses, 69.2, 30.8 and 30.8%, respectively; indistinct and circumscribed margins, 53.8 and 46.2%, respectively; an abundant blood flow, 53.8%; and posterior acoustic enhancement, 61.5%. The immunohistochemical (IHC) profile for 13 patients demonstrated that ER was not expressed in 100% of patients, PR and CerbB-2 were not present in 92.3% of patients, and P53 was present in 63.6% of patients. Therefore, metaplastic carcinoma of the breast exhibits more benign IHC features compared with invasive ductal carcinoma. In addition, it may be challenging to diagnose patients that do not possess posterior acoustic enhancement or express hormone receptors from other types of breast cancer. IntroductionMetaplastic carcinoma of the breast is a rare form of breast cancer and possesses a poorer prognosis than other common types of breast cancer (1). Metaplastic carcinoma exhibits the metaplastic transformation of glandular epithelium to squamous epithelium and mesenchymal tissue, and accounts for <5% of all breast cancers (2) and may contain glandular and non-glandular components with mixed epithelial and mesenchymal tissue. Involvement of the axillary lymph node is rare, with hematogenous metastasis occurring more commonly in cases of metaplastic carcinoma (1,3). Metaplastic carcinoma demonstrates a poorer prognosis and a higher risk of recurrence compared with other types of breast cancer (3). It typically presents as triple negative, therefore the effects of hormonotherapy are limited (3,4). Due to the heterogeneity of metaplastic carcinoma and its increased complexity compared with more common types of breast cancer, mixed chemotherapy regimens and dose schedules may be more effective and appropriate (2). Due to the distinction in surgical treatment and chemotherapy between metaplastic carcinoma and other breast cancers, it is particularly important to diagnose the tumor correctly (2). Metaplastic carcinoma demonstrates a number of benign features similar to invasive ductal carcinoma in mammograms and sonograms, and subsequently may be misdiagnosed as ...

show abstract

Section: Pathological Type Of Carcinoma Sonography ------------------mentioning

confidence: 99%

Metaplastic carcinoma of the breast: Imaging and pathological features

Bian

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Due to a rapidly growing and palpable large mass (≥ 5 cm) in MBC patients, MRM was the main surgical procedure in most series (Pitts et al, 1991;Gutman et al, 1995;Chao et al, 1999;Rayson et al, 1999;Al Sayed et al, 2006;Pezzi et al, 2007). However, BCS could not be precluded for appropriate MBC patients who had absolute or relative indications.…”

Section: Surgical Therapymentioning

confidence: 99%

“…Al Sayed et al reported that adjuvant chemotherapy was administered to nine patients and two of them experienced distant relapse upon first disease recurrence, and the 3-year OS for these patients were worse than those who did not receive adjuvant systemic therapy, however the difference was not statistically significant (Al Sayed et al, 2006). Chao et al found that 5 cases received adjuvant chemotherapy had a poorer OS than the patients who never take in chemotherapy (Chao et al, 1999). In the retrospective study by Bae et al, the 3-year DFS was worse than triple negative breast carcinoma for the lymphatic metastases (Bae et al, 2011).…”

Section: Chemotherapymentioning

confidence: 99%

“…MBC normally manifests as a rapidly growing and palpable large mass (≥5 cm), indicating a high potential for distant metastases. It is frequently lymph node negative (Oberman, 1987;Pitts et al, 1991;Gutman et al, 1995;Chao et al, 1999;Rayson et al, 1999). MBC is an aggressive disease which is more likely to be negative for estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) (Wargotz and Norris, 1989;Bae et al, 2011).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Current Progress in the Treatment of Metaplastic Breast Carcinoma

Hu¹,

Chen²,

Zhong³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Metaplastic breast cancer (MBC) is a rare type of breast carcinoma, characterized by various combinations of mesenchymal, adenocarcinoma and other epithelial components. MBC often manifests as a large mass, with low axillary lymph node involvement and poor prognosis. Knowledge and treatment patterns about MBC demographics, presentation and tumor characteristics are very limited. In clinical practice, MBC is usually treated based on the guidelines developed for infiltrating ductal carcinoma (IDC). The ideal treatment paradigm for MBC is unknown due to its low incidence and pathological variability, so potential predictors of treatment efficacy need to be explored. This review summarizes the current models and strategies for MBC according to the published literature.

show abstract

“…Patients with MBC were most commonly found to be older, with tumors of larger size and more advanced stage; they usually tested negative for ER and the tumors were poorly differentiated (11). Clinical examination usually reveals fast-growing palpable tumors (10,12). Most patients present with a well-defined mass over 2 cm in size, sometimes reaching 4-5 cm (3,10,13).…”

Section: Discussionmentioning

confidence: 99%